慢性肾脏疾病和调脂治疗

Chronic kidney disease and lipid-regulating treatment

慢性肾脏疾病和血脂异常常同时出现,两者均可增加心血管事件的发生率。调脂治疗对降低慢性肾脏疾病病人心血管事件发生率有利,慢性肾脏疾病病人调脂治疗的安全性值得重视。本文对不同阶段的慢性肾脏疾病病人在各种血脂异常时的调脂治疗策略作一综述。他汀类药物中以阿托伐他汀和氟伐他汀较为安全。

Chronic kidney disease and dyslipidemia may often coexist, both chronic kidney disease and dyslipidemia may increase the occurrence of cardiovascular events. Lipid-regulating treatment may be helpful to reduce the morbidity of cardiovascular events in chronic kidney disease patients, great attention should be paid for the safety of lipid-regulating treatment in chronic kidney disease. The strategies are reviewed for various types of dyslipidemia in various stages of chronic kidney disease in this paper. Among the stantins, atrovastin and flurastatin are safer.